|
|
|
| Clinical Efficacy and Safety of Phloroglucinol Combined with Pantoprazole in the Treatment of Abdominal Pain Patients with Acute Gastroenteritis |
| JIANG Peng |
| Department of Emergency, Henan Hongli Hospital, Xinxiang Henan 453400 |
|
|
|
|
Abstract 【Objective】 To evaluate the clinical efficacy and safety of pantoprazole combined with phloroglucinol in the treatment of abdominal pain associated with acute gastroenteritis. 【Methods】 Clinical data of 104 patients with abdominal pain due to acute gastroenteritis treated at Henan Hongli Hospital from March 2023 to October 2024 were retrospectively analyzed. Patients were divided into a control group and an observation group according to the treatment received, with 52 cases in each group. The control group received pantoprazole alone, while the observation group received phloroglucinol in addition to pantoprazole. The clinical efficacy, serum levels of inflammatory cytokines [interleukin-6 (IL-6) and interleukin-8 (IL-8)], clinical indices, and adverse reactions were compared between the two groups.【Results】 After treatment, the overall response rate in the observation group was 98.08% (51/52), which was significantly higher than that in the control group [86.54%(45/52); χ2=4.875, P=0.027]. The time to relief of abdominal pain and the duration of medication use in the observation group were significantly shorter than those in the control group (both P<0.05). After treatment, serum IL-6 and IL-8 levels in the observation group were significantly lower than those in the control group (both P<0.05). The total incidence of adverse reactions in the observation group was 7.69% (4/52), compared with 13.46% (7/52) in the control group, but the difference was not statistically significant (χ2=0.915, P=0.339).【Conclusion】 Pantoprazole combined with phloroglucinol shows good clinical efficacy in treating abdominal pain due to acute gastroenteritis, as it suppresses inflammatory responses, shortens treatment duration, and exhibits a favorable safety profile.
|
|
Received: 29 January 2026
|
|
|
|
|
|
[1] 李海娇,郭新慧,张云奇,等. 2017—2023年北京市房山区急性胃肠炎疫情流行特征分析[J]. 国际病毒学杂志,2024,31(6):516-519.
[2] 高飞,张剑峰,李敬晶,等. 黑龙江省2018年急性胃肠炎发病情况及其疾病负担分析[J]. 中国公共卫生,2023,39(4):505-508.
[3] Zhang P, HAO C, DI X, et al. Global prevalence of norovirus gastroenteritis after emergence of the GⅡ.4 Sydney 2012 variant: a systematic review and meta-analysis[J]. Front Public Health, 2024, 12: 1373322.
[4] 刘洪岩,杨浩,伍畅. 胃舒宁联合泮托拉唑对十二指肠溃疡患者临床治疗及血清学指标的影响[J]. 辽宁中医杂志,2025,52(1):91-93.
[5] 蒋闻弢,余瑞杭,贾韩静. 间苯三酚联合生长抑素治疗急性胰腺炎的临床效果研究[J]. 中国医药,2024,19(9):1353-1356.
[6] Kumari H, Kumar K, Kumar G, et al. Acute gastroenteritis: Its causes, maintenance, and treatment[J]. J Pharm Negat Results, 2022, 13(8): 5064-5078.
[7] 谢迪,何莲花,刘晖,等. 人诺如病毒感染引起的急性胃肠炎流行特征及其影响因素的研究进展[J]. 病毒学报,2024,40(1):140-150.
[8] 李婷婷,张晓旭,曲乐,等. 奥美拉唑联合阿托品对急性胃炎患者血清胃泌素和丙二醛水平的影响[J]. 中国现代医学杂志,2024,34(13):80-84.
[9] Liu Y F, Chen J. Application effect of phloroglucinol injection in elderly patients with spastic abdominal pain in emergency department[J]. World J Clin Cases, 2023, 11(23): 5440.
[10] 梁硕,宋立明,马建超,等. 复方乌贝方联合泮托拉唑治疗脾胃湿热型慢性浅表性胃炎的疗效及对胃肠道黏膜功能的影响[J]. 中国医院用药评价与分析,2025,25(1):69-71.
[11] Yildirim Ç, Pamukçu Günaydin G Ü L. Hyoscine-n-butylbromide in treating abdominal pain caused by gastroenteritis: a double-blind randomized placebo controlled study[J]. Turkish J Med Sci, 2024, 54(5): 887-892.
[12] 李世立,莫翠毅,许保. 不同剂量泮托拉唑治疗消化性溃疡并上消化道出血临床观察[J]. 中国药业,2022,31(13):91-93.
[13] Liu L B, Chen J J, Wang X M, et al. A rare case report of idiopathic renal infarction initially misdiagnosed as acute gastroenteritis[J]. Medicine(Baltimore), 2025, 104(27): e43081.
[14] 马建,胡修六,殷洪敏,等. 富马酸伏诺拉生片与泮托拉唑钠肠溶片治疗反流性食管炎的疗效及不良反应比较[J]. 中国现代医学杂志,2024,34(12):46-51. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(8): 1403-1406. |
|
|
|
|
2026, Vol. 43 
